Background
Active iodide accumulation marks an initial step in the biosynthesis of iodine-containing thyroid hormones in thyroid follicular cell [
1]. As an integral glycoprotein located at basolateral plasma membrane, sodium/iodide symporter (NIS) might efficiently mediate active iodide accumulation into thyroid follicular cell [
2]. Application of radioactive iodide isotopes has brought great advances in the diagnosis and treatment of thyroid cancer and provide a molecular basis for justifying radioiodide treatment for extrathyroidal malignancies [
3,
4]. Radioiodide treatment for ablating thyroid cancer metastases and remnants after thyroidectomy has been the most successful targeted internal radiotherapy [
5]. Its effectiveness is ultimately dependent on functional NIS expression at plasma membrane of tumor cells since deficient radioiodide accumulation is a major cause of treatment failure [
6]. NIS gene expression was frequently down-regulated in thyroid cancer and became almost totally silenced in poorly differentiated and anaplastic thyroid carcinomas [
7,
8]. Most studies demonstrated that iodide uptake by thyrocytes was basically dependent upon NIS transcriptional regulation [
8,
9]. NIS post-translational regulation occurred through its cellular traffic and stability and autophagy-lysosome pathway-mediated degradation, thus consequently affecting iodide uptake by thyrocytes [
10,
11]. Although several transcriptional and posttranscriptional mechanisms have been postulated for explaining a repression of NIS gene expression in thyroid tumors, further details regarding NIS-mediated resistance to radioiodide therapy remain unknown.
As a natural process in which subcellular membranes undergo dynamic morphological changes leading to the degradation of cellular proteins and cytoplasmic organelles, autophagy has been implicated in many physiological and pathophysiological conditions [
12]. It became typically up-regulated when cellular survival required intracellular nutrients and energy [
13]. Autophagy is important in the regulation of cancer development and progression and in determining the response of tumor cells to anticancer therapy. It might facilitate removal of damaged proteins or organelles during drug treatment in cancer cells and provide spare parts from degraded cellular components [
12]. Autophagy has also been implicated in the development and treatment of thyroid cancer [
14‐
16]. Heightened autophagy after multiple antitumor treatment regimens in thyroid cancer could enable tumor cells to be more sensitive to anticancer therapy [
15]. In contrast, pharmacologic or genetic inhibition of autophagy enhanced antitumor activity of vemurafenib, a selective and well-tolerated BRAF inhibitor, in thyroid cancer [
16]
. Protein degradation could occur through ubiquitin-proteasome system (UPS) or autophagy-lysosome pathway [
17]. Recent studies have confirmed that NIS protein was degraded in thyroid or mammary cells after an activation of autophagy-lysosome pathway [
11,
18]. However, the underlying molecular mechanism of autophagy regulating NIS degradation in thyroid cancer cells has remained illusive.
As a dynamic nuclear protein with vital roles during gene transcription, chromatin remodeling, DNA recombination and repair [
19], HMGB1 is also translocated into cytosol and extracellular space by multiple cellular stressors (e.g. protein aggregates, radiation, oxidation, chemotherapy and intracellular pathogens) [
20‐
22]. Dysfunction of intracellular and extracellular HMGB1 has been implicated in the pathogenesis of infections, cancer, neurodegeneration, aging and cardiac disease [
23‐
25]. An overexpression of HMGB1 was observed in leukemia, osteosarcoma, breast cancer, lung cancer and prostate cancer and there was also a strong association with their progression or prognosis [
20,
24,
25]. During tumor development and treatment, HMGB1 might play paradoxical roles in promoting both cell survival and death by regulating multiple signaling pathways, including immunity, genomic stability, proliferation, metastasis, metabolism, apoptosis and autophagy [
20,
26,
27]. Our previous studies have shown that HMGB1 plays an important role in leukemic pathogenesis and chemotherapeutic resistance [
24,
27,
28]. As a positive regulator of autophagy, intracellular HMGB1 interacts with Beclin-1 in leukemic cells leading to autophagosomal formation, an alternative mechanism of resistance to leukemic therapies [
27]. Although these studies have enriched our understanding of the role of HMGB1 in regulating autophagy and autophagy-related chemoresistance in leukemic cells, its possible role in the regulation of NIS degradation and radioiodide therapy by autophagy in thyroid cancer cells is unknown.
In the present study, we examined the expression of HMGB1 in various thyroid cancer cell lines and patient samples, HMGB1 involvement in autophagy, its influence on NIS degradation and iodide uptake of thyroid cancer cells and its relationship with ROS/AMPK/mTOR pathway. The objective was to obtain more insights into the function of HMGB1-mediated autophagy regulating NIS protein degradation.
Materials and methods
Reagents and cell culture
3-methyladenine (3-MA; #M9281), N-acetylcysteine (NAC; #A0737), diphenyleneiodonium chloride (DPI; #D2926) and rapamycin (#R8781) were supplied by Sigma-Aldrich (St. Louis, MO, USA); spautin-1 (#C3430) from Cellagen Technology (San Diego, CA, USA); TPC-1, K1, KTC-1 and FRO from American Type Culture Collection (Manassas, VA, USA); human bronchial epithelial cell HBE, normal human thyroid cell HT-ori3, acute myeloid leukemia cell HL-60 and chronic myelogenous leukemia cell K562 from Xiangya School of Medicine Type Culture Collection (Changsha, China). Following the procedures outlined previously [
4], we utilized FTC-133 and TPC-1 thyroid cancer cell lines (Additional file
1: Figure S1) stably expressing human NIS (hNIS). HL-60 and K562 cells were cultured in RPMI-1640 medium (Invitrogen, San Diego, CA) and FTC-133, TPC-1, K1, KTC-1, FRO, HBE and HT-ori3 cells in Dulbecco’s modified Eagle’s medium (DMEM; Hyclone, Thermo Fisher Scientific, Waltham, MA, USA) supplemented with 10% heat-inactivated fetal bovine serum (FBS; Thermo Fisher Scientific Inc., Waltham, MA) and 1% antibiotics (100 U/mL penicillin G & 100 mg/mL streptomycin) at 37 °C in a cell incubator with 5% CO
2 (Thermo Fisher Scientific Inc., USA).
Patients and samples collection
The study protocol was approved by the Ethics Committee of Hunan Cancer Hospital. And written informed consents were obtained from all participants before using clinical samples for researches. Thyroid cancer (
n = 36), thyroid adenoma (
n = 20), simple goiter (
n = 17) and normal thyroid tissues (
n = 15) were collected from January 2015 to December 2018. The diagnosis, stage and risk status of thyroid cancer were assessed in accordance with the criteria of National Comprehensive Cancer Network. The general clinical and laboratory profiles of patients were summarized in Table
1. Tissue samples were immediately immersed into liquid nitrogen after surgical removal and preserved at − 80 °C. Frozen tumor tissues and matching normal tissues from 88 cases were subjected to mRNA extraction for reverse transcription-polymerase chain reaction (RT-PCR). Samples from 36 patients with complete clinicopathological and follow-up information were selected for assessing the correlation of HMGB1 expression with clinical features based on RT-PCR analysis.
Table 1
Relationship between HMGB1 expression and clinicopathologic features in a validated cohort
Age (years) |
< 45 | 9 (50%) | 10 (55.6%) | P = 0.738 |
≥ 45 | 9 (50%) | 8 (44.4%) | |
Gender |
Male | 7 (66.7%) | 8 (22.2%) | P = 0.597 |
Female | 11 (33.3%) | 10 (77.8%) | |
Tumor size (cm) |
< 1 | 12 (66.7%) | 6 (33.3%) | P = 0.046 |
≥ 1 | 6 (33.3%) | 12 (66.7%) | |
Lymph node metastasis |
No | 13 (72.2%) | 6 (33.3%) | P = 0.019 |
Yes | 5 (27.8%) | 12 (66.7%) | |
Histological type |
PTC | 9 (50%) | 10 (55.6%) | P = 0.738 |
FTC | 9 (50%) | 8 (44.4%) | |
Clinical stage |
I + II | 13 (72.2%) | 7 (38.9%) | P = 0.044 |
III + IV | 5 (27.8%) | 11 (61.1%) | |
Lentivirus, plasmid transfection and RNA interference
HMGB1 small hairpin RNA (shRNA) lentiviral knockdown (GeneCopoeia, Guangzhou, China) or shRNA non-target control (NTC) were packaged with HIV-based packaging mix (GeneCopoeia) for infecting FTC-133/TPC-1 cells for establishing cells constitutively repressing HMGB1. Stable clones were selected by puromycin. The HMGB1 shRNA oligonucleotide sequences were as follows: HMGB1 shRNA: 5′ - CCGGGCAGATGACAAGCAGCCTTATCTCGAGATAAGGCTGCTTGTCATCTGCTTTTT-3′; Non-silencing shRNA (control shRNA) were used as mock-transfected controls (target sequence: TTCTCCGAACGTGTCACGT). Human SOD1-siRNA (target sequence: GGUGGAAAUGAAGAAAGUAC) was transfected with Lipofectamine RNAiMAX reagent (for siRNA) according to the manufacturer’s instructions (Invitrogen). After incubating 48-h with RNA interference (RNAi), culture medium was replaced before subsequent treatments.
Reverse transcription polymerase chain reaction (RT-PCR)
Following the procedures outlined previously [
24], total RNA was isolated from patient tissues and FTC-133 cells using Trizol reagent (Invitrogen, USA) according to the manufacturer’s instructions. RNA concentration and purity were measured with a spectrophotometer at A260 and A260/280 respectively. And RNA was reverse-transcribed into cDNA using a Primescript™ RT reagent kit (Invitrogen) according to the manufacturer’s instructions. The sequences of primers used were as follows: for β-actin: forward, 5′-TCCTTCCTGGGCATGGAGTC-3′ and reverse 5′-GTAACGCAACTAAGTCATAGTC-3′; for HMGB1: forward, 5′-TTTCAAACAAAGATGCCACA-3′ and reverse, 5′-GTTCCCTAAACTCCTAAGCAGATA-3′; for hNIS: forward, 5′-GTCGTGGTGATGCTAAGTGGC-3′ and reverse, 5′-ATTGATGCTGGTGGATGCTGT-3′. β-Actin was used as an internal control for evaluating the relative expressions of HMGB1 and hNIS. The conditions for polymerase chain reaction (PCR) to HMGB1 were as follows: denaturation at 94 °C for 2 min, followed by 30 cycles of 94 °C for 30 s, 56 °C for 30 s (β -actin: 50 °C for 30 s), 72 °C for 30 s and then by a 5 min elongation at 72 °C. The conditions for polymerase chain reaction (PCR) to hNIS were: denaturation at 94 °C for 2 min, followed by 30 cycles of 94 °C for 30 s, 61 °C for 30 s (β-actin: 50 °C for 30 s), 72 °C for 30 s and then by a 2 min elongation at 72 °C. PCR products were analyzed with 1.0% agarose gel electrophoresis, ethidium bromide (EB) staining, photographed and scanned using Band Leader software for gray-scale semiquantitative analysis.
Quantitative real-time PCR (qRT-PCR)
TRIzol (Invitrogen) was employed for isolating total cell RNA and cDNA synthesized with PrimeScript™ RT Master Mix (Takara Biomedical Technology Co., Ltd., Beijing, China). A 7900 Real-Time PCR System (Applied Biosystems, Foster City, CA) with AceQ qPCR SYBR Green Master Mix (High ROX Premixed Vazyme Biotech Co., Ltd., Nanjing, China) was used for performing quantitative PCR (qPCR). Relative mRNA expression was standardized using the housekeeping gene β-actin forward (5′-CATTAAGGAGAAGCTGTGCT-3′) and reverse (5′-GTTGAAGGTAGTTTCGTGGA-3′). The following human primers were used in this study: NIS forward (5′-GCGTGGCTCTCTCAGTCAA-3′) and reverse (5′-GCGTCCATTCCTGAGCTG-3′). Cycling conditions were as follows: 98 °C for 2 min, followed by 40 cycles of 98 °C for 10 s, 60 °C for 10 s and 68 °C for 30 s. The relative gene expressions were calculated by comparative CT method. Samples were examined in triplicate.
Antibodies, preparation of subcellular fractions and Western blot
The following commercially available antibodies were used: murine anti-HMGB1 (#H00003146-M08), rabbit anti-Beclin-1 (#NB500–249) and rabbit anti-LC3 (#NB600–1384) were obtained from Novus (Littleton, CO, USA); rabbit antibodies against superoxide dismutase 1 (SOD1)(# ab51254), tubulin (#ab18251), fibrillarin (#ab4566) and actin (#ab3280) from Abcam (Cambridge, MA, USA); rabbit antibodies against phospho(p)-mTORS2448 (#2971), mTOR (#2972), p-p70S6KT389(#9205), p70S6K (#9202), p-AMPKαT172 (#9282), AMPKα (#2532), horseradish peroxidase (HRP)-conjugated goat anti-rabbit IgG (7074) and HRP-conjugated goat antimouse IgG (7072) from Cell Signaling Technology (Danvers, MA, USA); antibody to p62 (#Sc-28359) from Santa Cruz Biotechnology (Dallas, TX, USA); antibody against human NIS (#ab83816) from Abcam (Cambridge, MA, USA). NIS has a hyper-glycosylated form of molecular weight of approximately 70 to 90 kDa and a hypo-glycosylated form of 60 kDa. The hyper-glycosylated NIS represents the mature and main form of iodide-pumping NIS on plasma membrane [
29]. A hyper-glycosylated form of molecular weight of 69 kDa was detected in the present study.
Cells were rinsed with PBS, collected and resuspended in lytic buffer (Beyotime, Beijing, China) and maintained on ice for 15 min. Cytosolic/nuclear extracts and total cellular lysates were prepared using the NE-PER nuclear and cytoplasmic extraction kit (Piece, Rockford, USA) according to the manufacturer’s instructions. Protein concentrations of the extracts were measured with BCA assay (Pierce, Rockford, USA) and equalized with the extraction reagents. Whole cell lysates were separated by 8, 10% or 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and subsequently electrophoretically transferred onto polyvinylidene difluoride (PVDF) blotting membranes (Beyotime, Beijing, China). The membranes were blocked with 5% non-fat dry milk in Tris-buffered saline containing Tween 20 (TBST; 50 mM Tris [pH 7.5], 100 mM NaCl, 0.15% Tween-20), incubated with diluted primary antibodies for 12 h at 4 °C, and rinsed thrice with TBST for 10 min. Then the membranes were incubated with different secondary antibodies for 12 h at 4 °C and hybridization was detected by enhanced chemiluminescent reagents (Pierce, Waltham, MA) after rinsing thrice with TBST for 10 min. Membranes were exposed to radiographic film and the expression levels of targeted proteins quantified. A BandScan 5.0 system was employed for quantifying and analyzing specific bands via Western blot.
Immunofluorescent analysis
Cells were fixed in 4% formaldehyde for 30 min at room temperature prior to cell permeabilization with 0.1% Triton X-100 (4 °C, 10 min). After saturating with PBS containing 2% bovine serum albumin for 1 h at room temperature, the samples were processed for immunofluorescence with anti-LC3B antibody (L7543, Sigma) followed by Alexa Fluor 488-conjugated immunoglobulin and DAPI (Sigma). Between all incubation steps, cells were rinsed thrice for 3 min with PBS containing 0.2% bovine serum albumin. Fluorescent signals were analyzed using an Olympus Fluoview 1000 confocal microscope (Olympus Corp, Tokyo, Japan).
Immunohistochemistry
Both patient samples and murine tumors were fixed in 10% formalin for 24 h. After dehydration and paraffin embedding, the specimens were sliced into 5-μm thick sections by a microtome (Leica, Wetzlar, Germany) and mounted on glass slides. The expressions of HMGB1, Beclin1 and NIS were measured by immunostaining. After deparaffinization and rehydration, the sections were pressure-cooked for 2 min in an antigen retrieval buffer (0.01 M citrate buffer, pH 6.0) for unmasking antigens. Then the sections were incubated with murine anti-rat HMGB1, Beclin1 and NIS monoclonal antibodies (1:200, Cat. No. 113802, Biolegend, San Diego, CA) at 4 °C overnight respectively, followed by biotinylated anti-murine IgG secondary antibody (ZSGB-bio, Beijing, China) for 1 h at 37 °C and streptavidin-HRP (ZSGB-bio) for 30 min at 37 °C. Furthermore, HRP substrate DAB (3, 3-diaminobenzidine; ZSGB-bio, China) was utilizing for developing and visualizing the immunostained samples whereas cell nuclei were counter-stained with hematoxylin. Images were acquired with an Olympus BX51 microscope for assessing the proportion of positively stained cells.
Electron microscopy
Cells were collected and fixed in 2.5% glutaraldehyde for at least 3 h. Then the cells were treated with 2% paraformaldehyde at room temperature for 60 min and 0.1% glutaraldehyde in 0.1 M sodium cacodylate for 2 h and followed by post-fixing with 1% OsO4 for 1.5 h. After a second rinsing, cells were dehydrated with graded acetone and finally embedded in Quetol 812. Ultrathin sections were observed under an H7500 electron microscope (Hitachi, Tokyo, Japan).
Determination of ROS generation
The intracellular alterations of ROS were determined by measuring the oxidative conversion of cell-permeable 2′,7′-dichlorofluorescein diacetate (DCFH-DA) into fluorescent dichlorofluorescein (DCF) on a fluorospectrophotometer (F4500, Hitachi, Tokyo, Japan) according to the methods described previously [
22] or by flow cytometry. In brief, cells exposed to different treatments were collected, rinsed with D-Hank’s buffer and incubated with DCFH-DA at 37 °C for 30 min. Then DCF fluorescence of 20,000 cells was detected by a fluorospectrophotometer at an excitation wavelength of 488 nm and an emission wavelength of 535 nm. Or fluorescent intensity of DCF was measured by flow cytometry. Incremental production of ROS was expressed as a percentage of control.
Measurement of intracellular ATP level
The cellular levels of ATP were detected by Enhanced ATP Assay Kit (Beyotime Biotechnology) according to the manufacturer’s instructions. Briefly assay buffer was gently mixed with substrate at room temperature. Then mixed reagent 100 μl was loaded into each well and incubated for 15 min at room temperature. Then luminescence was measured by a microplate reader (Beckman Coulter). Incremental production of ATP was expressed as a percentage of control.
Radionuclide uptake studies
The procedures of iodide uptake were previously described [
4]. Cells (1 × 10
5 cells/well) were seeded in 24-well plates and then treated accordingly.
131I solution (Atom Gaoke, Beijing, China) (175 KBq) was added and the cells were incubated for 1 h at 37 °C. Cells were washed twice with ice-cold phosphate-buffered saline (PBS) and dissolved in 0.1% NaOH. Cell lysates were collected and cellular radioactive accumulation was measured by a gamma counter (Zonkia Scientific Instruments Inc., Anhui, China). For determining the radionuclide uptake in relation to incubation time, cells were cultured with 175 KBq
131I for 5, l0, 20, 30, 60, 90 and 120 min. And radionuclide absorption was determined as above.
Tumor cell xenograft model
Male nude mice (4–6 weeks of age) were purchased from Xiangya Medical College Animal Laboratory (Changsha, China). All experiments were approved by our institutional Animal Ethics Committee. The animals were raised in pathogen-free conditions with a 12-h light-dark cycle with an ad libitum supply of water and food. At one week after adaptive feeding, tumor model was established by a subcutaneous injection of 200 μL of sterile PBS containing 1 × 10
6 cells FTC-133 or TPC-1 cell transfected with HMGB1 shRNA or control shRNA via right armpit. As previously described [
30], food was withdrawn at 18 h, but not water, before experiment when murine tumors grew > 150 mm
3. For each experiment, 20 mice were randomly divided into the following four groups: (a) control shRNA model without hunger (vehicle group); (b) control shRNA model with hunger (hunger group); (c) HMGB1 shRNA model without hunger (vehicle group) and (d) HMGB1 shRNA model with hunger (hunger group).
In vivo tumor imaging
After establishing a xenograft tumor model, nude mice received a tail injection of 37 MBq of 99mTCO4 -. Static SPECT images were acquired after 10 min using a gamma camera (GE Healthcare, Waukesha, WI, USA) with a low-energy high-resolution collimator.
Biodistribution
Nude mice were sacrificed at the end of SPECT scan (90-min timepoint). Blood, heart, liver, spleen, lung, thyroid, stomach and tumor tissues were harvested and weighed. And radioactivity was measured by a gamma counter and the corresponding CPM count/mg tissue calculated.
Statistical analysis
All statistical analyses were performed using SPSS 19.0 software (IBM Corp, Armonk, NY, USA). And the results were expressed as mean ± standard deviation (SD). Group means were compared by Student’s t-test for independent data. All P-values were two-tailed and P < 0.05 was deemed as statistically significant.
Discussion
Radioiodide accumulation in thyroid tissue has been exploited clinically for diagnosing, treating and following up thyroid pathologies for several decades. The capability of thyroid epithelia of concentrating I
− is ultimately dependent on functional NIS expression at plasma membrane. NIS has been used as a therapeutic gene approach for treating cancers through its ability of concentrating therapeutic doses of radionuclide in target cells [
2,
3]. Our study implied that HMGB1 was directly involved in the positive regulation and maintenance of autophagy in HBSS-treated thyroid cancer cells, thereby promoting NIS degradation and lowering iodide uptake. A depletion of HMGB1 suppressed starvation-induced NIS degradation and boosted iodide uptake in vitro and in vivo through a ROS/AMPK/mTOR-dependent pathway. Thus our findings may provide novel therapeutic options for thyroid cancer patients already on radioiodide therapy.
HMGB1, an abundant nonhistone protein, has been shown to play a central role in inducing autophagy. And HMGB1-induced autophagy was essential for drug resistance of osteosarcoma, leukemia, lung cancer and breast cancer [
39]. Recent studies have implied that autophagy was involved in several steps of thyroid tumor initiation and progression as well as in therapeutic resistance and therefore it could be exploited for therapeutic applications [
40]. However, HMGB1 expression and its function in mediating autophagy in thyroid cancer have been poorly elucidated. Here HMGB1 expression became up-regulated in samples derived from patients of PTC, FTC and thyroid cancer cell lines. Conversely, their levels were lower in thyroid adenoma, simple goiter and normal thyroid samples. Furthermore, its expression levels were correlated with clinicopathologic features of thyroid cancer patients. Higher related to lymph node metastasis risk, later clinical stage and tumor size, suggesting a potential contributory role of HMGB1 in tumorigenesis of thyroid cancer.
Recently mounting evidence has implied that NIS post-transcriptional regulation is an important mechanism during an uptake of iodide. Riedel et al. [
10] have showed that the presence of NIS post-translational regulation through its cellular traffic and stability, thus consequently regulating iodide uptake by thyrocytes. As an important post-transcriptional mechanism, autophagy-mediated processes regulated NIS protein degradation. NIS protein became degraded in mammary cells after an activation of autophagy-lysosome pathway through an inhibition of MEK [
18]. As reported by Cazarin et al. [
11], AMPK activation might regulate NIS protein degradation through an autophagy-lysosome pathway in rat thyroid cells. It hinted at a potential contributory effect of autophagy on NIS protein degradation. Our previous studies have confirmed that HMGB1 is a positive regulator of autophagy in leukemic cells, rendering leukemic cells resistant to chemotherapeutic drugs. Here HBSS treatment induced autophagy of thyroid cancer cells and a targeted deletion of HMGB1 cancelled out this starvation-induced autophagy. Additionally, HBSS-induced autophagy lowered NIS expression and iodide uptake and using autophagy inhibitors blocked the HMGB1-mediated regulation of starvation-induced autophagy and boosted iodide uptake. In contrast, rapamycin, an autophagy inducer, enhanced the HMGB1-mediated regulation of starvation-induced autophagy and reduced iodide uptake. However, NIS expression and iodide uptake showed no reduction in HMGB1 knockdown cells after a co-treatment of 3-MA or rapamycin. It hinted at a dominant role of HMGB1 in regulating autophagy and NIS expression and iodide uptake were highly correlated with autophagy.
Both ROS and autophagy play important roles in cellular stress responses through a variety of complicated signaling pathways and molecules. Many stimuli of inducing ROS generation, such as nutrient starvation, mitochondrial toxins and hypoxia, also induce autophagy [
41]. Tang et al. [
21] have showed that ROS generated during starvation and rapamycin treatment served as signaling molecules of initiating autophagy and promoting HMGB1 cytosolic translocation from nucleus. Our experimental data also indicated that HMGB1 translocation during autophagy was ROS-dependent in thyroid cancer cells. Pharmacological inhibition of ROS production suppressed HBSS-induced autophagy, whereas a knockdown of SOD1 expression promoted HBSS-induced autophagy. Furthermore, a pre-treatment of NAC led to a decrease of HMGB1 cytosolic translocation while there was an increase with a depletion of SOD1 expression. These results suggested that ROS was sufficient for inducing HMGB1 translocation and sustaining autophagy in thyroid cancer cells. Compared with normal cells, both ROS and autophagy became altered in cancer cells. On one hand, ROS could induce autophagy through several distinct mechanisms involving a catalase activation of Atg4 and a disturbance of mETC [
42]. On the other hand, defective autophagy increased oxidative stress in tumor cells [
43]. Kang et al. [
44] have showed HMGB1 was a crucial regulator of autophagy as a cellular defense mechanism in response to oxidative stress/injury. Here it was further confirmed that a knockdown of HMGB1 causing defective autophagy suppressed HBSS-induced ROS generation and a co-treatment of rapamycin failed to restore the ROS levels.
As an evolutionarily conserved serine/threonine kinase, AMPK plays a vital role in sustaining cellular metabolic balance and regulating NIS protein degradation [
11,
45]. Both AMP/ATP ratio and ROS were essential for activating AMPK [
37]. Here a knockdown of HMGB1 had no effect upon ATP levels, supporting that ROS, rather than ATP, was not involved in HMGB1-mediated autophagy induced by HBSS. Previous studies have examined the role of AMPK in thyroid disorder, such as nodular goiter and thyroid tumorigenesis. An activation of AMPK might be beneficial for thyroid diseases [
46,
47]. And mTOR signaling pathway has been shown to play an important role in autophagy. Activating this pathway could suppress autophagy and enhance cellular growth and proliferation in both normal and tumor cells [
38]. Studies have shown that activation of AMPK but inhibition of mTOR inducing autophagy has been regarded as an important mechanism for thyroid cancer therapy [
48,
49]. Our previous study has demonstrated that HMGB1 is an intrinsic regulator of autophagy in leukemic cells through mTOR pathway [
24]. In this study, we provide evidence that knockdown of HMGB1 inhibited starvation-induced autophagy, NIS degradation and AMPK phosphorylation in vitro and in vivo, but not for mTOR and P70S6K phosphorylation as well as NAC co-treatment in control group. Additionally, knockdown of HMGB1 restored the accumulated
99mTcO4
− of thyroid cancer cells xenograft after hunger treatment in nude mice. These preclinical results suggest that HMGB1-mediated autophagy regulating NIS degradation could be a potential target for radioiodide therapy in thyroid cancer.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.